Benzinga | Feb 23, 2021 05:58AM EST

Baird Upgrades Vertex Pharmaceuticals to Outperform, Raises Price Target to $252

Baird analyst Brian Skorney upgrades Vertex Pharmaceuticals (NASDAQ:VRTX) from Neutral to Outperform and raises the price target from $220 to $252.